Cytosorbents Corporation (CTSO)

Market Cap	80.77M
Revenue (ttm)	35.33M
Net Income (ttm)	-16.11M
Shares Out	62.61M
EPS (ttm)	-0.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	56,429
Open	1.270
Previous Close	1.280
Day's Range	1.252 - 1.300
52-Week Range	0.700 - 1.610
Beta	1.05
Analysts	Buy
Price Target	5.50 (+329.69%)
Earnings Date	Aug 12, 2025

About CTSO

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. The company’s flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflammation, organ failure, cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, su...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1997
• Employees: 149
• Stock Exchange: NASDAQ
• Ticker Symbol: CTSO
• Website: https://www.cytosorbents.com

Financial Performance

In 2024, Cytosorbents's revenue was $35.59 million, an increase of 14.51% compared to the previous year's $31.08 million. Losses were -$20.72 million, -29.16% less than in 2023.

Analyst Summary

According to 2 analysts, the average rating for CTSO stock is "Buy." The 12-month stock price target is $5.5, which is an increase of 329.69% from the latest price.

Price Target

$5.5

(329.69% upside)

Analyst Consensus: Buy